[Cabozantinib (renal cell carcinoma) - benefit assessment according to §35a Social Code Book V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018000053
German
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iqwig.de/download/A17-56_Cabozantinib_Nutzenbewertung-35a-SGB-V_V1-0.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Germany
MeSH Terms
- Anilides
- Carcinoma, Renal Cell
- Humans
- Kidney Neoplasms
- Pyridines
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.